GIC Sub-Industry 'Biotechnology': 200+ results
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | 12m vs SPY |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
396B | 52.5% | 69.8% | 35.7% | 170 | 7.07% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
178B | 82.2% | 70.3% | 53.5% | 25.5 | 2.65% |
| GILD Gilead Sciences |
Biotechnology
HIV, COVID-19, Hepatitis, Oncology |
150B | 81.9% | 60.5% | 64.8% | 18.8 | 15.3% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Gene Therapy |
119B | 86.3% | - | 32.8% | 32.7 | -8.90% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
84.9B | 74.6% | 18.9% | 41.8% | 19.2 | -11.8% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
52.6B | 58.2% | - | 21.2% | - | 18.7% |
| ARGX argenx |
Biotechnology
FcgRn-Blocker, MusK-Agonist |
49.3B | 71.1% | - | 37.2% | 34.0 | 0.14% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Cold-Relief |
44.1B | 69.9% | 56.6% | 17.4% | 22.0 | -8.98% |
| INSM Insmed |
Biotechnology
Liposomal Antibiotic, DPP1 |
37.5B | 35.8% | - | 47.5% | - | 96.7% |
| ONC BeiGene |
Biotechnology
BTK Inhibitor, PD-1 Antibody, PARP |
35.5B | 64.7% | - | 48.7% | 628 | 57.5% |
| NTRA Natera |
Biotechnology
Panorama, Horizon, Vistara |
33.4B | 48.0% | - | 69.5% | - | 16.4% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis, Spinal |
27.5B | 64.3% | - | 35.3% | 17.1 | -1.66% |
| BNTX BioNTech SE |
Biotechnology
Cancer Immunotherapies |
25.1B | 14.3% | 1.0% | -17.6% | - | -21.9% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, Immunotherapies |
25.0B | 11.0% | 1.0% | -25.2% | - | -32.7% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Orenitram, Unituxin |
21.9B | 87.9% | - | 50.6% | 18.3 | 8.84% |
| GMAB Genmab AS |
Biotechnology
Antibody Therapies, Oncological |
21.2B | 78.1% | - | 46.1% | 15.0 | 29.2% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
21.0B | 88.9% | - | 58.1% | 18.1 | 18.4% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
20.8B | 29.1% | - | 77.0% | - | 133% |
| RGC Regencell |
Biotechnology
Herbal, Capsule, Syrup, Extract |
20.5B | 37.0% | - | 52.2% | - | -17.2% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
15.1B | 31.9% | - | 87.2% | - | 80.8% |
| BIM Biomerieux |
Biotechnology
Chromogenic Media, Blood Culture |
15.0B | 78.1% | 59.9% | -25.5% | 34.5 | -18.1% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Diagnostics |
14.7B | 68.3% | 13.0% | 49.2% | 31.6 | 25.0% |
| BBIO BridgeBio Pharma |
Biotechnology
ATTR-CM, Achondroplasia |
14.2B | 44.9% | - | 88.0% | - | 94.3% |
| SMMT Summit Therapeutics |
Biotechnology
Ivonescimab, Bispecific Antibody |
14.2B | 30.8% | - | -22.4% | - | -23.4% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine, Psychiatric |
13.5B | 84.6% | - | -0.67% | 32.3 | -23.4% |
| MRNA Moderna |
Biotechnology
Vaccines, Respiratory, Oncology |
13.4B | 22.6% | - | -2.35% | - | -6.69% |
| IONS Ionis |
Biotechnology
RNA-Targeted, Neurological, Rare |
13.2B | 22.0% | 1.0% | 66.7% | - | 88.4% |
| EXEL Exelixis |
Biotechnology
Cancer, Medicines, Tablets |
12.4B | 91.7% | - | 63.0% | 18.3 | 3.43% |
| ASND Ascendis Pharma AS |
Biotechnology
TransCon, Hormone, Parathyroid |
12.4B | 36.3% | - | 63.7% | - | 32.9% |
| BMRN Biomarin |
Biotechnology
Enzyme Replacement, Growth |
11.8B | 79.2% | - | -51.8% | 22.3 | -31.8% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, MASH, Thyroid |
11.7B | 32.0% | - | 53.1% | - | 34.7% |
| RNA Avidity Biosciences |
Biotechnology
RNA Therapeutics, Antibody |
10.9B | 33.0% | - | 76.6% | - | 111% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Zodasiran |
8.97B | 54.2% | - | 70.4% | - | 187% |
| HALO Halozyme |
Biotechnology
Enzyme, Injection, Antibody |
8.83B | 89.3% | - | 45.4% | 15.4 | 9.65% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 28.4% | - | 84.4% | - | 1,425% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.11B | 31.9% | - | 84.8% | - | 1,305% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin, Clotting |
7.65B | 65.3% | 1.88% | -8.90% | 13.8 | 2.95% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Cardiac |
7.64B | 38.1% | - | 58.4% | - | 12.3% |
| NUVL Nuvalent |
Biotechnology
Ros1 Inhibitor, Alk Inhibitor |
7.64B | 30.9% | - | 63.6% | - | 16.6% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
7.42B | 33.4% | - | 56.3% | - | 263% |
| KRYS Krystal Biotech |
Biotechnology
Gene Therapy, Rare Skin Diseases |
7.22B | 83.7% | - | 83.0% | 37.3 | 60.9% |
| RYTM Rhythm |
Biotechnology
Imcivree, Setmelanotide, Obesity |
6.74B | 42.1% | - | 55.1% | - | 62.7% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.17B | 78.2% | - | 61.1% | 8.94 | 41.8% |
| BLTE Belite Bio |
Biotechnology
Tinlarebant, LBS-009, Retinal |
6.15B | 34.2% | - | 62.6% | - | 134% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
6.03B | 30.0% | - | 12.1% | - | -53.0% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
5.98B | 31.2% | - | 66.6% | - | 65.0% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
5.46B | 49.3% | - | 69.5% | - | 286% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
5.46B | 27.0% | - | 66.0% | - | 15.4% |
| APGE Apogee |
Biotechnology
Monoclonal Antibodies, Atopic |
5.29B | 36.3% | - | 86.8% | - | 60.0% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
5.24B | 29.5% | - | 33.5% | - | -4.68% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene Editing, CAR-T |
5.13B | 32.2% | - | 47.0% | - | 19.8% |
| PTGX Protagonist |
Biotechnology
Peptide, Hepcidin, Integrin |
5.01B | 64.1% | - | 63.1% | 122 | 81.4% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.85B | 89.2% | - | -13.2% | 14.3 | -14.8% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
4.85B | 33.8% | - | 61.7% | - | 157% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.84B | 28.7% | - | 65.9% | - | 696% |
| ACAD ACADIA |
Biotechnology
Pimavanserin, Trofinetide |
4.53B | 76.1% | - | 58.3% | 17.3 | 22.4% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, Tg-1701 |
4.52B | 70.6% | - | -15.6% | 10.3 | -16.6% |
| INDV Indivior Ordinary |
Biotechnology
Buprenorphine, Sublingual |
4.44B | 74.1% | 1.48% | 63.5% | 36.2 | 145% |
| FOLD Amicus Therapeutics |
Biotechnology
Enzyme Replacement, Small |
4.42B | 52.0% | - | 65.0% | - | 28.5% |
| CGON CG Oncology |
Biotechnology
Bladder Cancer, Oncolytic |
4.37B | 32.7% | - | 64.0% | - | 51.9% |
| ADMA ADMA Biologics |
Biotechnology
Immunoglobulin, Hepatitis |
4.28B | 84.3% | - | 6.89% | 20.9 | -11.1% |
| SRRK Scholar Rock |
Biotechnology
Antibody, Myostatin-Inhibitor |
4.25B | 27.0% | - | 14.6% | - | -14.9% |
| MIRM Mirum |
Biotechnology
Livmarli, Cholbam, Chenodal |
4.22B | 47.3% | - | 70.1% | - | 70.3% |
| LEGN Legend Biotech |
Biotechnology
CAR-T Therapy, Multiple Myeloma |
4.17B | 29.3% | - | -51.1% | - | -42.5% |
| LGND Ligand |
Biotechnology
Vaccines, Antivirals, Oncology |
4.07B | 49.7% | 1.0% | 57.0% | 91.0 | 47.7% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, LDL-C |
3.90B | 27.7% | - | 38.1% | - | 7.36% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
3.82B | 40.2% | - | 83.0% | - | 355% |
| ACLX Arcellx |
Biotechnology
DdCAR, Anitocabtagene Autoleucel |
3.72B | 38.9% | - | -8.56% | - | -17.9% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK5211, VK0612, VK2735 |
3.65B | 29.4% | - | 5.25% | - | -34.6% |
| APLS Apellis |
Biotechnology
EMPAVELI, SYFOVRE, Pegcetacoplan |
3.45B | 76.1% | - | -53.3% | 75.8 | -38.2% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, MAU868, VT-109 |
3.39B | 26.6% | 2.43% | 68.6% | - | 17.0% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.32B | 63.4% | - | 33.8% | 111 | -16.7% |
| CNTA Centessa |
Biotechnology
Sleep Disorder Drug, Ox2R Agonist |
3.28B | 33.1% | - | 41.1% | - | 20.6% |
| XENE Xenon |
Biotechnology
Epilepsy, Depression, Bipolar |
3.26B | 30.1% | - | 21.0% | - | -12.6% |
| IDYA Ideaya Biosciences |
Biotechnology
Kinase Inhibitor, Mat2a Inhibitor |
3.19B | 23.4% | - | 75.6% | - | 26.5% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.19B | 41.8% | - | 51.7% | - | 58.3% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.16B | 66.9% | - | 50.8% | 92.7 | 76.0% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.09B | 27.4% | - | 41.1% | - | 29.7% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
3.03B | 34.7% | - | 59.4% | - | 49.1% |
| IRON Disc Medicine |
Biotechnology
Bitopertin, DISC-0974, DISC-3405 |
2.99B | 35.6% | - | 28.7% | - | 6.38% |
| DYN Dyne Therapeutics |
Biotechnology
Antisense Oligos, FORCE Platform |
2.93B | 31.5% | - | 7.35% | - | -7.69% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
2.90B | 38.5% | - | 61.2% | - | 103% |
| BEAM Beam Therapeutics |
Biotechnology
Base Editing Therapies |
2.80B | 28.1% | - | 17.0% | - | 12.1% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.79B | 89.6% | - | 10.2% | 13.3 | -16.7% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Cytokine-Fusion |
2.78B | 66.2% | - | -20.0% | - | -5.82% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, eIF2B Activator |
2.67B | 25.6% | - | -0.41% | - | -23.4% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
2.64B | 31.5% | - | 35.9% | - | 191% |
| EWTX Edgewise |
Biotechnology
EDG-5506, EDG-7500, Oral |
2.64B | 30.2% | - | 14.3% | - | -18.4% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immunotherapy |
2.60B | 33.3% | - | 68.1% | - | 35.2% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.46B | 30.2% | - | -42.9% | - | -85.0% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, CNS TYK2 |
2.44B | 50.9% | - | 62.4% | - | 154% |
| RXRX Recursion |
Biotechnology
REC-994, REC-2282, REC-4881 |
2.43B | 33.3% | - | -45.3% | - | -42.4% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.38B | 29.6% | - | 44.6% | - | 21.2% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor, ADC |
2.32B | 33.9% | - | 71.7% | - | 66.2% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Prader-Willi, Rare |
2.31B | 29.6% | - | -31.0% | - | -20.2% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.18B | 38.2% | - | 39.9% | - | 13.6% |
| GLPG Galapagos |
Biotechnology
Oncology, Immunology, CAR-T |
2.18B | 25.8% | - | 11.8% | - | -0.41% |
| RARE Ultragenyx |
Biotechnology
Enzyme, Gene, Antibody, Metabolic |
2.17B | 36.8% | - | -38.4% | - | -53.7% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
2.13B | 36.4% | - | 19.2% | - | -23.6% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology, Neurology |
2.05B | 31.9% | - | -68.4% | - | -38.5% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136 |
2.05B | 35.1% | - | 70.7% | - | 377% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.00B | 93.6% | - | 71.5% | 27.1 | 59.8% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
1.95B | 62.4% | - | -4.65% | 148 | -48.5% |
| MESO Mesoblast |
Biotechnology
Cell Therapy, Stem Cell |
1.94B | 36.5% | - | 4.85% | - | -13.3% |
| ZBIO Zenas BioPharma |
Biotechnology
Obexelimab, ZB002, ZB004, ZB001 |
1.91B | 31.4% | - | 58.2% | 2.61 | 120% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.88B | 33.8% | - | 46.7% | - | -0.83% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, CBL-B Inhibitor |
1.87B | 35.8% | - | 14.1% | - | -17.5% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.83B | 26.7% | - | 37.2% | - | 32.5% |
| CLDX Celldex |
Biotechnology
Antibody, Monoclonal, Bispecific |
1.82B | 31.5% | - | 8.45% | - | -11.7% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.81B | 37.2% | - | 38.0% | - | 4.33% |
| NNNN Anbio |
Biotechnology
Antigen, Immunoassay |
1.80B | 73.2% | - | 50.8% | 685 | 522% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-007, ERAS-601 |
1.77B | 37.1% | - | 61.6% | - | 189% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
1.75B | 30.5% | - | 62.0% | - | 41.9% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense, Oligonucleotide |
1.75B | 71.4% | - | 55.2% | 45.0 | 184% |
| PHVS Pharvaris BV |
Biotechnology
Deucrictibant, Oral Capsule, Oral |
1.68B | 24.4% | - | 71.3% | - | 31.2% |
| BCRX BioCryst |
Biotechnology
Antiviral, Hae, Complement, Protein |
1.67B | 72.1% | - | -45.2% | - | -29.5% |
| IMCR Immunocore Holdings |
Biotechnology
Immunotherapy, Oncology, Melanoma |
1.67B | 41.4% | - | -1.89% | - | -10.9% |
| AGIO Agios Pharm |
Biotechnology
Pyrimidine Kinase Activator |
1.66B | 35.7% | - | -41.5% | - | -32.9% |
| GLUE Monte Rosa |
Biotechnology
MGD Pipeline, MRT-2359, MRT-6160 |
1.65B | 71.3% | - | 86.3% | 79.1 | 251% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.64B | 26.4% | - | 83.3% | - | 61.3% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.63B | 36.9% | - | 47.4% | - | 76.7% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF Biopolymer, Anti-Il6 |
1.63B | 47.0% | - | 88.1% | - | 200% |
| TYRA Tyra Biosciences |
Biotechnology
FGFR, Precision, Platform |
1.62B | 30.5% | - | 80.2% | - | 58.0% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.58B | 38.4% | - | -6.17% | - | 29.1% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 63.6% | - | 6.66% | 50.7 | -23.8% |
| BHVN Biohaven |
Biotechnology
Neurology, Immunology, Oncology |
1.51B | 32.5% | - | -64.7% | - | -75.8% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitors, Brain-Penetrant |
1.49B | 34.2% | - | 77.7% | - | 202% |
| MEDCL Medincell |
Biotechnology
Antipsychotic, Analgesic |
1.48B | 58.6% | - | 40.8% | - | 34.0% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.47B | 37.0% | - | -64.9% | 20.6 | -69.7% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.44B | 37.9% | - | 17.3% | - | 114% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.44B | 34.0% | 85.7% | -2.06% | 56.1 | -15.1% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Trial, Anxiety |
1.43B | 32.4% | - | 72.8% | - | 89.6% |
| MBX MBX Biosciences |
Biotechnology
Peptide Prodrug, GLP-1 Antagonist |
1.42B | 32.9% | - | 90.8% | 4.13 | 141% |
| CAPR Capricor |
Biotechnology
Deramiocel, Exosome Vaccine |
1.39B | 28.3% | - | 58.9% | - | 61.4% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.36B | 33.8% | - | 68.2% | - | 143% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 44.3% | - | 223% |
| RLAY Relay Therapeutics |
Biotechnology
RLY-2608, RLY-4008, RLY-8161 |
1.35B | 35.3% | - | 37.6% | - | 37.6% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.35B | 28.7% | 1.0% | 70.1% | - | 85.0% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.33B | 25.9% | - | 23.9% | - | -14.7% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.31B | 16.4% | - | 25.7% | - | 17.9% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.31B | 66.6% | - | 55.9% | - | 41.9% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
1.29B | 30.2% | - | 2.68% | - | -16.8% |
| MLTX MoonLake |
Biotechnology
Sonelokimab, Nanobody, IL-17A |
1.28B | 28.4% | - | 4.42% | - | -68.7% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.1% | - | 91.3% | - | 136% |
| ANAB AnaptysBio |
Biotechnology
Rosnilimab, ANB032, ANB033 |
1.25B | 25.2% | - | 84.9% | - | 173% |
| IMTX Immatics |
Biotechnology
TCR Bispecifics, ACT Cell |
1.25B | 21.7% | - | 39.0% | - | 24.3% |
| SANA Sana Biotechnology |
Biotechnology
Islet Cell Therapy, CAR-T Cell |
1.21B | 35.3% | - | 39.5% | - | 12.5% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.20B | 33.3% | - | -6.32% | - | -3.24% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.18B | 39.8% | - | -2.33% | 3.62 | -16.6% |
| SVRA Savara |
Biotechnology
Inhaled Immunostimulant, Orphan |
1.17B | 22.5% | - | 79.8% | - | 75.8% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Esophagus |
1.16B | 53.8% | - | 48.8% | - | 25.6% |
| PVLA Palvella |
Biotechnology
Rapamycin Gel, Rare Dermatology |
1.15B | 25.6% | - | 69.0% | - | 560% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.10B | 48.5% | - | 43.2% | - | 61.3% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, Tgf-Beta |
1.10B | 46.0% | - | 36.1% | - | 89.7% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.08B | 23.4% | - | -42.2% | - | -27.5% |
| BBOT BridgeBio Oncology |
Biotechnology
KRAS Inhibitor, HER2 Therapy |
1.01B | 47.6% | - | 14.3% | - | 4.30% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Bispecific |
992M | 14.5% | - | -10.2% | - | -43.0% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
973M | 42.7% | - | -26.6% | - | -66.3% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle Radiotherapy |
971M | 37.1% | - | 47.6% | - | 408% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticle-Based Radiotherapy |
966M | 49.0% | - | 49.6% | - | 511% |
| CMPX Compass |
Biotechnology
Trocimig, CTX-471, CTX-8371 |
952M | 32.7% | - | 65.6% | - | 137% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
931M | 26.5% | - | 45.7% | - | 57.1% |
| ESPR Esperion |
Biotechnology
Bempedoic Acid, Ezetimibe |
920M | 55.2% | - | 17.3% | - | 19.9% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
918M | 31.5% | - | 0.45% | - | -24.1% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
912M | 50.3% | - | 25.2% | 13.4 | -33.3% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
907M | 31.4% | - | 23.2% | 3.08 | 11.8% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
903M | 86.7% | - | -34.1% | 22.6 | -43.1% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
891M | 34.7% | - | 20.5% | - | -2.34% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapy, PD-L1 Inhibitor, HBV |
889M | 29.8% | - | 72.6% | - | 17.2% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
865M | 27.9% | - | 37.8% | - | 191% |
| VLA Valneva SE |
Biotechnology
Vaccines, Chikungunya, Lyme, Zika |
859M | 25.7% | - | 21.3% | - | 66.5% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
855M | 27.3% | - | -22.7% | - | -63.6% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
852M | 39.9% | - | -47.2% | - | -74.7% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor, Oral |
849M | 39.7% | - | 56.8% | - | 64.6% |
| DBVT DBV Technologies |
Biotechnology
Viaskin Peanut, Viaskin Milk |
835M | 38.3% | - | 55.3% | - | 161% |
| KURA Kura Oncology |
Biotechnology
Ziftomenib, Tipifarnib, KO-2806 |
831M | 56.2% | - | 15.5% | - | 5.36% |
| VIR Vir Biotechnology |
Biotechnology
Antibodies, Vaccines, T-Cell |
814M | 29.6% | - | -10.1% | - | -50.3% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
810M | 30.3% | - | 16.1% | - | -28.4% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment, Oral |
789M | 36.7% | - | 37.5% | - | 3.79% |
| GYRE Gyre Therapeutics |
Biotechnology
Pirfenidone, Hydronidone, F573 |
750M | 61.6% | 1.0% | -3.22% | 195 | -35.4% |
| RIGL Rigel |
Biotechnology
Kinase Inhibitor, Blood Disorder |
741M | 93.2% | - | 56.6% | 6.60 | 83.8% |
| RGNX Regenxbio |
Biotechnology
Gene Therapy, Retinal Diseases |
739M | 19.1% | - | 65.3% | - | 79.4% |
| ATXS Astria Therapeutics |
Biotechnology
Navenibart, STAR-0310, Monoclonal |
735M | 36.2% | - | 32.8% | - | 38.9% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Autologous Renal |
728M | 38.5% | - | -19.5% | - | 15.0% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
722M | 60.5% | - | 74.8% | 14.2 | 282% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editor |
711M | 40.6% | - | 10.0% | - | 24.4% |
| DRUG Bright Minds |
Biotechnology
Serotonin Agonists, Epilepsy |
676M | 27.9% | - | 91.7% | - | 109% |
| IRWD Ironwood |
Biotechnology
Linaclotide, Apraglutide, IW-3300 |
660M | 57.7% | - | 17.6% | 22.6 | 1.94% |
| EBS Emergent |
Biotechnology
Vaccines, Antitoxins |
649M | 52.0% | 1.0% | 12.7% | 9.22 | 7.12% |
| CGEM Cullinan Oncology |
Biotechnology
Zipalertinib, CLN-978, CLN-619 |
644M | 31.4% | - | 29.8% | - | -19.5% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
630M | 32.7% | - | -49.1% | - | -38.9% |
| MYGN Myriad Genetics |
Biotechnology
Oncology Tests, Womens Health |
618M | 36.6% | 1.0% | -42.3% | - | -64.0% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapy, Ocular |
596M | 38.8% | - | 2.12% | - | 3.43% |
| ENGN enGene Holdings |
Biotechnology
Bladder Cancer Therapy, Gene |
590M | 29.4% | - | 21.4% | - | -11.9% |
| IVVD Invivyd |
Biotechnology
Antibody, Covid-19, Influenza |
585M | 40.4% | - | 46.1% | - | 386% |
| KROS Keros Therapeutics |
Biotechnology
KER-050, KER-012, KER-065 |
585M | 69.0% | - | 41.1% | 12.3 | 26.0% |
| DNA Ginkgo Bioworks |
Biotechnology
Cell Engineering, Biosecurity |
583M | 16.7% | - | -22.2% | - | -10.1% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002 |
579M | 36.0% | - | 36.7% | - | 139% |
| SLS Sellas Life |
Biotechnology
Cancer Immunotherapy, CDK9 |
569M | 37.3% | - | 60.4% | - | 274% |
| IVA Inventiva |
Biotechnology
Lanifibranor, Odiparcil, TGF-ß |
557M | 45.0% | - | 31.5% | - | 118% |